Dianthus Therapeutics announces exclusive licensing agreement with Nanjing Leads Biolabs for DNTH212

Reuters

10/16

Dianthus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> announces exclusive licensing agreement with Nanjing Leads Biolabs for DNTH212

Dianthus Therapeutics Inc. announced it has entered into an exclusive licensing agreement with Nanjing Leads Biolabs Co., Ltd. for DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor. Under the terms of the agreement, Dianthus will pay Leads Biolabs up to $38 million, including $30 million in upfront and near-term milestone payments and an additional $8 million milestone upon initiation of a Dianthus-led Phase 1 study. Leads Biolabs is also eligible to receive up to $962 million in development, regulatory approval, and sales-based milestones, as well as tiered royalties on ex-Greater China net sales. Dianthus will hold exclusive rights to develop and commercialize DNTH212 globally outside of Greater China. The company estimates a pro forma cash balance of approximately $525 million following the transaction and reaffirms its cash runway into 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546649-en) on October 16, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2575710580"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575710580\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575710580?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-16 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575710580","market":"nz","top_or_hot":-1,"title":"Dianthus Therapeutics announces exclusive licensing agreement with Nanjing Leads Biolabs for DNTH212","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Dianthus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> announces exclusive licensing agreement with Nanjing Leads Biolabs for DNTH212\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNTH\">Dianthus Therapeutics Inc.</a> announced it has entered into an exclusive licensing agreement with Nanjing Leads Biolabs Co., Ltd. for DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor. Under the terms of the agreement, Dianthus will pay Leads Biolabs up to $38 million, including $30 million in upfront and near-term milestone payments and an additional $8 million milestone upon initiation of a Dianthus-led Phase 1 study. Leads Biolabs is also eligible to receive up to $962 million in development, regulatory approval, and sales-based milestones, as well as tiered royalties on ex-Greater China net sales. Dianthus will hold exclusive rights to develop and commercialize DNTH212 globally outside of Greater China. The company estimates a pro forma cash balance of approximately $525 million following the transaction and reaffirms its cash runway into 2028.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546649-en) on October 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dianthus Therapeutics announces exclusive licensing agreement with Nanjing Leads Biolabs for DNTH212</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDianthus Therapeutics announces exclusive licensing agreement with Nanjing Leads Biolabs for DNTH212\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-16 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Dianthus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> announces exclusive licensing agreement with Nanjing Leads Biolabs for DNTH212\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNTH\">Dianthus Therapeutics Inc.</a> announced it has entered into an exclusive licensing agreement with Nanjing Leads Biolabs Co., Ltd. for DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor. Under the terms of the agreement, Dianthus will pay Leads Biolabs up to $38 million, including $30 million in upfront and near-term milestone payments and an additional $8 million milestone upon initiation of a Dianthus-led Phase 1 study. Leads Biolabs is also eligible to receive up to $962 million in development, regulatory approval, and sales-based milestones, as well as tiered royalties on ex-Greater China net sales. Dianthus will hold exclusive rights to develop and commercialize DNTH212 globally outside of Greater China. The company estimates a pro forma cash balance of approximately $525 million following the transaction and reaffirms its cash runway into 2028.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546649-en) on October 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DNTH","symbol_name":"Dianthus Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL2cr6SH:1","article_id":"2575710580","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575710580","pubTimestamp":1760612417,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Dianthus Therapeutics Inc. announced it has entered into an exclusive licensing agreement with Nanjing Leads Biolabs Co., Ltd. for DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor. Under the terms of the agreement, Dianthus will pay Leads Biolabs up to $38 million, including $30 million in upfront and near-term milestone payments and an additional $8 million milestone upon initiation of a Dianthus-led Phase 1 study. Leads Biolabs is also eligible to receive up to $962 million in development, regulatory approval, and sales-based milestones, as well as tiered royalties on ex-Greater China net sales. Dianthus will hold exclusive rights to develop and commercialize DNTH212 globally outside of Greater China. The company estimates a pro forma cash balance of approximately $525 million following the transaction and reaffirms its cash runway into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ac","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DNTH":"Dianthus Therapeutics Inc.","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","BK4112":"金融交易所和数据"},"translate_title":"Dianthus Therapeutics宣布与南京Leads Biolabs就DNTH212达成独家许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNTH":0.9,"NDAQ":0.9},"content_text":"Dianthus Therapeutics announces exclusive licensing agreement with Nanjing Leads Biolabs for DNTH212\n    \n\nDianthus Therapeutics Inc. announced it has entered into an exclusive licensing agreement with Nanjing Leads Biolabs Co., Ltd. for DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor. Under the terms of the agreement, Dianthus will pay Leads Biolabs up to $38 million, including $30 million in upfront and near-term milestone payments and an additional $8 million milestone upon initiation of a Dianthus-led Phase 1 study. Leads Biolabs is also eligible to receive up to $962 million in development, regulatory approval, and sales-based milestones, as well as tiered royalties on ex-Greater China net sales. Dianthus will hold exclusive rights to develop and commercialize DNTH212 globally outside of Greater China. The company estimates a pro forma cash balance of approximately $525 million following the transaction and reaffirms its cash runway into 2028.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546649-en) on October 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}